Two pharmaceutical companies, Pfizer and Sagent Pharmaceuticals, said the shortage is because of heightened demand and manufacturing delays. The other four drugmakers include Fresenius Kabi, Hikma Pharmaceuticals, Sky Pharma and Techdow USA.
As of Jan. 16, the heparin sodium solutions are back ordered until late January through March.
The shortage has been ongoing for months.
“[With] heparin flushes, we’re still having to use different products here at our health system than we normally want to,” Erin Fox, PharmD, the senior pharmacy director at Salt Lake City-based University of Utah Health who helps run ASHP’s drug shortage website, told Becker’s on Jan. 10.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
